Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT SATCHER and TIANHONG PAN.
Connection Strength
3.608
-
BIGH3 mediates apoptosis and gap junction failure in osteocytes during renal cell carcinoma bone metastasis progression. Cancer Lett. 2024 Aug 01; 596:217009.
Score: 0.961
-
Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo. Mol Cancer Ther. 2020 06; 19(6):1266-1278.
Score: 0.719
-
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia. 2018 01; 20(1):32-43.
Score: 0.612
-
Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Lett. 2015 Aug 28; 365(1):89-95.
Score: 0.514
-
All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. J Bone Oncol. 2021 Dec; 31:100399.
Score: 0.200
-
Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene. 2021 Jul; 40(27):4592-4603.
Score: 0.196
-
Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells. J Cell Sci. 2015 Dec 15; 128(24):4629-41.
Score: 0.132
-
Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 2014; 9(2):e89880.
Score: 0.118
-
Unbiased metastatic niche-labeling identifies estrogen receptor-positive macrophages as a barrier of T cell infiltration during bone colonization. bioRxiv. 2024 May 10.
Score: 0.060
-
Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater. 2024 04 01; 178:83-92.
Score: 0.059
-
Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget. 2017 Sep 26; 8(43):74987-75006.
Score: 0.038